Strata Skin Sciences (SSKN)
(Delayed Data from NSDQ)
$3.02 USD
0.00 (0.00%)
Updated Jul 12, 2024 11:50 AM ET
4-Sell of 5 4
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SSKN 3.02 0.00(0.00%)
Will SSKN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SSKN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SSKN
New Strong Buy Stocks for February 14th
Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Tops Revenue Estimates
SSKN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tabula Rasa Healthcare (TRHC) Reports Q3 Loss, Tops Revenue Estimates
Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
Other News for SSKN
STRATA Skin Sciences Pre-Announces Second Quarter 2024 Financial Results
STRATA Skin Sciences Sponsors Webinars Featuring Leading Dermatologists Discussing Benefits of XTRAC® and TheraClear®X Devices
Strata Skin Sciences sponsors webinars on XTRAC, TheraClearX devices
SSKN Stock Earnings: Strata Skin Sciences Misses EPS, Misses Revenue for Q2 2023
STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal